CRISPR-Cas9

gene edits scientists gene editing CRISPR

Biotech

Editas cashes in on Vertex Cas9 licensing agreement for $57M

Against the backdrop of a Cas9 patent battle that refuses to die, Editas is cashing in a chunk of the rights from Vertex to the tune of $57 million.

James Waldron Oct 4, 2024 5:06am

gene editing edit gene CRISPR

CRISPR gene therapy for deafness works in young adult mice

Jul 11, 2024 9:15am

start race starting block runners go advance

Intellia showcases durability of one-and-done HAE option

Jun 2, 2024 8:00am

Graphic of a fork in the road with arrows pointing in either direction

Intellia opts out of hemophilia gene editing work with Regeneron

Mar 22, 2024 11:21am

gene edits scientists gene editing CRISPR

Vertex pays Editas $100M to use gene-editing tech

Dec 13, 2023 12:46pm

Graphic image of someone cutting off a row of stick figures symbolizing employees

CRISPR Therapeutics laid off staff a week after positive AdComm

Nov 22, 2023 1:36pm